This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
stock-price-movement: Archive
What Makes Entergy (ETR) a New Buy Stock
by Zacks Equity Research
Entergy (ETR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ETRPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
HOWLNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Travelers (TRV) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Travelers (TRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TRVNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Kanzhun (BZ) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Kanzhun (BZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BZNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About PSEG (PEG) Rating Upgrade to Buy
by Zacks Equity Research
PSEG (PEG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PEGNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Clover Health Investments (CLOV) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CLOVPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
HighPeak Energy (HPK) Upgraded to Buy: Here's Why
by Zacks Equity Research
HighPeak Energy (HPK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HPKPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Community West Bancshares (CWBC) Upgraded to Buy: Here's Why
by Zacks Equity Research
Community West Bancshares (CWBC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CWBCNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Allstate (ALL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Allstate (ALL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ALLNegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Here's Why United Natural (UNFI) Looks Ripe for Bottom Fishing
by Zacks Equity Research
United Natural (UNFI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
UNFINegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
VSTMPositive Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Boston Scientific (BSX) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
BSXPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
BSXPositive Net Change
momentum-stocks price-change stock-price-change stock-price-movement stocks-moving-today
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ARMPNegative Net Change NEOPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength?
by Zacks Equity Research
Innoviva (INVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
INVAPositive Net Change NVONegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
WidePoint (WYY) Soars 12.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
WidePoint (WYY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
WYYPositive Net Change PDFSNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
eGain (EGAN) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
eGain (EGAN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EGANPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Webtoon (WBTN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Webtoon (WBTN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WBTNNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
TPG RE Finance Trust (TRTX) Upgraded to Buy: Here's Why
by Zacks Equity Research
TPG RE Finance Trust (TRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TRTXNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Bellway (BLWYY) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Bellway (BLWYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BLWYYNo Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Columbia Financial (CLBK) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Columbia Financial (CLBK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CLBKNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
XFORPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Canadian Imperial Bank (CM) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Canadian Imperial Bank (CM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CMPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
LENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LENZNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Home BancShares (HOMB) Upgraded to Buy: Here's Why
by Zacks Equity Research
Home BancShares (HOMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HOMBNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank